APhA supports efforts to remove hurdles to patient-centered care models

MARY WARNER | February 7, 2017

article image
Patients and health care providers often face barriers when putting patient-centered care models into practice. One such potential barrier is a health plan cost-control process requiring providers to obtain approval before performing a service to qualify for payment. This process can delay or interrupt medical services, divert significant resources from patient care, and complicate medical decisions.

Spotlight

Clear Genetics (YC W17)

We are reinventing the way people around the world access genetic expertise. Clear Genetic is developing a medical platform for patients, genetic counselors and physicians. With the burgeoning industry of genetic testing, every patient today needs easy access to genetic experts. We are building an experience that leverages technology and best medical practice to provide vastly improved patient care around genetics.

OTHER ARTICLES

Comparing HydroxyChloroquine Trials

Article | April 1, 2020

One minor side effect of the pandemic is that perhaps more people will learn about what drug research and clinical trials can really be like. Today’s example: we have a clinical trial of hydroxychloroquine from Wuhan that has just published on a preprint server. What’s good is that this one is blinded, randomized, and controlled (like the earlier hydroxychloroquine which one I blogged about here from Zhejiang University, so we can actually talk about it rather than just spend all our time wondering what the heck is going on.

Read More

Pfizer Won’t Win the Coronavirus Pharma War

Article | March 6, 2020

Shares of Pfizer jumped more than 6% on Wednesday, after the company announced a plan to test some of its antiviral products as a potential treatment for the coronavirus from China. More than 35 million shares traded on the news — about 48% more than normal — as investors looked for any positive news from the pharma community after the recent selloff. So, does this mean that Pfizer stock is turning the corner?

Read More

Pricing of drugs – at what cost?

Article | February 27, 2020

We go into a doctor’s office and leave with a diagnosis and a prescription. Next we stop by the pharmacy. In Germany, if your insurance is not private, you mostly don’t even know the price of your drug because it’s paid for directly by your insurance. You only notice the 5-10 Euros copay. But how is a drug priced in Germany? And (how) does data play a role in helping pharma secure an attractive price point? Let’s fast forward directly to the launch of a new drug. At the time of launch, the pharmaceutical company has to present patient level evidence of the drug’s added value compared to existing comparative therapies. In the first year, however, the drug’s price can be defined freely by the company.

Read More

Merck’s Patient-Centric Clinical Trial Recruiting

Article | March 4, 2020

Everyone in pharma knows that product success depends on the results of clinical trials — but we don’t usually hear from the people who are involved in running them. Recently, four Clinical Research Managers (CRM) from Merck (known as MSD outside the United States and Canada) discussed how Merck is overcoming the barriers to clinical trial recruitment by adopting a patient-centric process — a model that affects their trials top to bottom, from design through implementation. Each of the panel members manages clinical trials, serving as the main point of interaction with the Clinical Research Associates (CRAs) on research requirements, goals, and resources, including recruiting and retention.

Read More

Spotlight

Clear Genetics (YC W17)

We are reinventing the way people around the world access genetic expertise. Clear Genetic is developing a medical platform for patients, genetic counselors and physicians. With the burgeoning industry of genetic testing, every patient today needs easy access to genetic experts. We are building an experience that leverages technology and best medical practice to provide vastly improved patient care around genetics.

Events